Ocugen Initiates Phase 2/3 Trial for Gene Therapy OCU410ST, Targeting Stargardt Disease with Promising Preliminary Results
ByAinvest
Saturday, Jul 19, 2025 3:24 am ET1min read
OCGN--
Ocugen has dosed the first patient in its Phase 2/3 GARDian3 clinical trial for OCU410ST, a gene therapy for Stargardt disease. The trial follows promising preliminary results from the previous Phase 1 trial, showing slower lesion growth and improved visual acuity. The company aims to submit a Biologics License Application for OCU410ST by 2027.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet